Key Takeaways
- MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA, with a molecular weight of approximately 2174 Da.
- The only published human dosing data comes from a 2022 pilot by Lee et al. (n=20 older adults), which tested 2 mg and 4 mg subcutaneous doses with no serious adverse events but no efficacy endpoints powered for significance.
- Exercise physiologically elevates circulating MOTS-c in humans (Lee et al., Cell Metabolism, 2019); whether exogenous injection replicates the same signaling context is mechanistically uncertain.
- Vendors frequently sell products labeled as MOTS-c with purity unverified by independent third-party mass spectrometry; a COA from the vendor's own lab is not equivalent to independent testing.
- MOTS-c loses to metformin and berberine on every clinical evidence metric; it is mechanistically interesting but currently a pre-clinical compound with one human pilot.
What Is MOTS-c Peptide and Should You Buy It?
Table of Contents
- What is MOTS-c and where does it come from?
- Mechanism with specific numbers
- Evidence ledger: what the research actually shows
- What most pages get wrong about MOTS-c
- Stability and formulation: the sourcing gotcha
- Honest head-to-head: MOTS-c vs. alternatives
- How to read a MOTS-c COA before you buy
- Dosing context from published research
- Legal and regulatory status
- FAQ
- Sources
What Is MOTS-c and Where Does It Come From?
MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA type-c. It was first characterized by Lee et al. in 2015 (Cell Metabolism) as a peptide encoded not in the nuclear genome but in mitochondrial DNA, specifically within the 12S ribosomal RNA region. This makes it a mitochondrial-derived peptide (MDP), a class of small signaling peptides released from mitochondria under metabolic stress.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The mature peptide is 16 amino acids long (MRWQEMGYIFYPRKLR) with a molecular weight of approximately 2174 Da. Under cellular energy stress, MOTS-c translocates from the mitochondrial matrix to the cytoplasm and then to the nucleus, where it engages transcriptional programs. This dual mitochondrial-nuclear role distinguishes it from most peptides synthesized in the cytoplasm.
How Does MOTS-c Work? Mechanism With Specific Numbers
The core mechanistic paper (Lee et al., 2015, Cell Metabolism) identified two interlocking pathways:
- AMPK activation: MOTS-c inhibits the folate cycle and de novo purine synthesis, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator. This is the same upstream node that metformin partially engages. MOTS-c does not directly bind AMPK; the activation is indirect via metabolite accumulation.
- Glucose uptake and insulin sensitivity: In the 2015 mouse study, daily intraperitoneal injection at 5 mg/kg prevented high-fat-diet-induced insulin resistance. Skeletal muscle glucose uptake increased in treated mice, consistent with AMPK-mediated GLUT4 translocation. The caveat: 5 mg/kg in mice does not translate directly to human mg/kg dosing by simple body weight scaling.
- NF-kB modulation: Subsequent work (Kim et al., 2018, Aging Cell) showed MOTS-c suppresses NF-kB signaling in aged cells, suggesting an anti-inflammatory role independent of pure metabolic effects. This is mechanistically plausible but does not prove a clinical anti-aging effect.
- Exercise-induced release: Lee et al. (Cell Metabolism, 2019) demonstrated that circulating MOTS-c concentrations measurably increase in human subjects during aerobic exercise. This is one of the few pieces of human physiological data available and establishes MOTS-c as an endogenous exercise signal, not just a laboratory construct.
What the mechanism does NOT prove: AMPK activation in mice or cell culture does not guarantee the same magnitude of effect in healthy adult humans who are not in an energy-deficit state. AICAR accumulation as an intermediary is well-characterized in vitro; whether exogenous subcutaneous MOTS-c recreates this intracellular accumulation at the same concentrations is pharmacokinetically unestablished.
Evidence Ledger: What the Research Actually Shows
| Claim | Best evidence type | Effect direction | Key source | Confidence |
|---|---|---|---|---|
| Improves insulin sensitivity in high-fat-diet obese mice | Animal RCT (mice) | Positive | Lee et al., Cell Metabolism 2015 | Moderate (animal) |
| Activates AMPK via AICAR accumulation | Cell culture / mechanism | Positive | Lee et al., Cell Metabolism 2015 | Moderate (mechanism) |
| Circulating levels rise with aerobic exercise in humans | Human observational physiology | Positive | Lee et al., Cell Metabolism 2019 | Moderate |
| Suppresses NF-kB inflammatory signaling in aged cells | Cell culture | Positive | Kim et al., Aging Cell 2018 | Low (in vitro only) |
| Safe and tolerable at 2 mg and 4 mg SC in older adults | Human pilot (n=20, no placebo control) | No serious AEs observed | Lee et al., 2022 pilot | Low (very small, uncontrolled) |
| Improves physical performance or metabolic markers in humans | No powered human RCT completed | Unknown | None available | Very low (no data) |
| Extends lifespan or healthspan in mammals | Mouse study (Reynolds et al., Nature Communications 2021) | Positive in aged mice | Reynolds et al., Nat Commun 2021 | Low (animal, aged-mouse model) |
What Most Pages Get Wrong About MOTS-c
The majority of MOTS-c content online presents mouse data as if it were human clinical data. Three specific errors appear repeatedly:
- The 5 mg/kg dose myth: Many articles cite 5 mg/kg from the 2015 mouse study and then suggest human doses of 5-10 mg without explaining that allometric scaling from mice to humans requires division by a body surface area conversion factor (typically a factor of roughly 12 for mice-to-human), making the equivalent human dose substantially lower in mg/kg terms. This is not a proven clinical dose; it is an extrapolation.
- Treating the exercise physiology paper as a dosing justification: The observation that MOTS-c rises naturally during exercise is cited as proof that injecting it will produce exercise-like benefits. This is a non-sequitur. A natural pulsatile rise with a specific cellular context is not equivalent to sustained elevation from exogenous injection in a resting state.
- No disclosure of the COA problem: Almost no vendor page explains that many research peptide COAs are generated by the same facility that synthesizes the product, with no independent verification. Third-party HPLC and MS confirmation is the only reliable purity check.
Stability and Formulation: The Sourcing Gotcha
MOTS-c is a relatively small peptide but shares degradation vulnerabilities with the broader class:
- Lyophilized powder: Stable at -20°C for an extended period when kept dry and away from light. The lyophilization process removes water, which is the primary vector for hydrolytic peptide bond cleavage. A product that arrives at room temperature without dry ice after a multi-day transit has likely experienced thermal stress.
- Reconstituted solution: Once dissolved in bacteriostatic water (0.9% benzyl alcohol), refrigerate at 4°C and use within 2-4 weeks. Benzyl alcohol inhibits microbial growth but does not prevent chemical degradation. Repeated freeze-thaw cycles after reconstitution cause aggregation and loss of bioactive peptide; aliquot before freezing if long storage is planned.
- Why room-temperature shipping is a problem at the chemistry level: Peptide hydrolysis follows Arrhenius kinetics. Each 10°C rise in temperature approximately doubles the reaction rate. A lyophilized peptide exposed to 30°C for several days accumulates meaningfully more hydrolytic damage than one kept at 4°C. You cannot verify this damage by visual inspection; the powder looks identical. Only mass spectrometry would reveal truncated fragments.
- The endotoxin variable: Bacterial lipopolysaccharide (endotoxin) contamination in improperly manufactured peptides causes fever, inflammatory responses, and confounds any research result. A credible COA will include a Limulus amebocyte lysate (LAL) endotoxin test result. Absence of this test from a COA is a red flag.
- Acetate vs. TFA salt: Peptides synthesized by solid-phase synthesis often retain trifluoroacetate (TFA) as a counter-ion from cleavage steps. TFA at injection doses is cytotoxic. Reputable suppliers convert to acetate salt; confirm this on the COA.
Honest Head-to-Head: MOTS-c vs. Real Alternatives
| Attribute | MOTS-c | Metformin | Berberine | Exercise (aerobic) |
|---|---|---|---|---|
| Mechanism | AMPK (indirect, via AICAR) | AMPK (indirect, via mitochondrial complex I inhibition) | AMPK (direct and indirect) | AMPK + multiple pathways |
| Human RCT evidence | None (one small pilot) | Extensive (decades, thousands of patients) | Multiple RCTs for glucose/lipids | Extensive |
| Approved / legal OTC | No (research compound) | Yes (prescription) | Yes (supplement, most jurisdictions) | Yes |
| Route of administration | Subcutaneous injection only | Oral tablet | Oral capsule | N/A |
| Known side effects (human data) | Unknown (insufficient data) | GI upset, B12 depletion, lactic acidosis (rare) | GI upset, drug interactions | Injury risk if excessive |
| Cost | High ($30-100+ per mg from research suppliers) | Very low (generic) | Low | Low to moderate |
| Where MOTS-c loses | On every clinical evidence metric, MOTS-c loses to metformin and berberine. It is mechanistically novel, not clinically superior. | |||
How to Read a MOTS-c COA Before You Buy
When evaluating any MOTS-c for sale, request the Certificate of Analysis and check these specific items:
| What to check | Acceptable standard | Red flag |
|---|---|---|
| HPLC purity | 98% or higher for research grade | 95% or below, or no chromatogram provided |
| Molecular weight (mass spec) | ~2174 Da confirmed by ESI-MS or MALDI | No MS data, or MW not matching expected value |
| Endotoxin test | LAL test result below 1 EU/mg | No endotoxin test listed at all |
| Counter-ion | Acetate salt stated explicitly | TFA salt, or counter-ion not stated |
| Testing laboratory | Named independent third-party lab | Internal QC only, or lab name withheld |
| Lot number and date | Present and recent | No lot number (cannot trace to batch) |
A vendor that refuses to share the COA or provides only a summary table without an underlying chromatogram is selling you trust, not verified chemistry.
Dosing Context From Published Research
| Study | Model | Dose used | Route | Duration |
|---|---|---|---|---|
| Lee et al., Cell Metabolism 2015 | Mice (obese, HFD) | 5 mg/kg/day | Intraperitoneal | Several weeks |
| Reynolds et al., Nat Commun 2021 | Aged mice | Not publicly detailed at single value | Intraperitoneal | Weeks to months |
| Lee et al., 2022 pilot (human) | Adults 65+ years (n=20) | 2 mg or 4 mg flat dose | Subcutaneous | Single or short series |
No published human data exists for daily chronic dosing. The 2022 pilot is unpowered for efficacy conclusions. Protocols circulating in online communities are extrapolations from animal data, not validated human protocols.
What Is the Legal Status of MOTS-c for Sale in the US?
MOTS-c is not approved by the FDA as a drug or dietary supplement. In the United States it may be sold by research chemical companies for laboratory and investigational use, with explicit labeling that it is not for human consumption. Purchasing for personal use occupies a legal gray area; no federal prosecution of individual buyers for small quantities has been publicly reported, but the legal risk is real and jurisdiction-specific.
WADA's 2025 Prohibited List does not name MOTS-c explicitly, but the list includes a catch-all category covering substances with similar biological effects to named peptide hormones and growth factors. Athletes in tested sports should treat MOTS-c as presumptively prohibited and seek a formal WADA ruling before any use.
In some countries (Canada, Australia, UK) peptides not approved as medicines are regulated more strictly than in the US. Importation may trigger customs interception.
FAQ
What is MOTS-c and why are people buying it?
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA (12S rRNA region) that activates AMPK and influences glucose metabolism and insulin sensitivity. Buyers are primarily interested in metabolic optimization, exercise performance, and longevity applications, though human RCT evidence remains limited.
Is MOTS-c FDA approved?
No. MOTS-c is not FDA approved for any indication. It is sold as a research compound for laboratory or investigational use only and cannot legally be marketed as a drug or dietary supplement for human use in the United States.
What dose of MOTS-c is used in research?
Mouse studies have used doses in the range of 5 mg/kg administered intraperitoneally. The single published human pilot study by Lee et al. (2022) in older adults used 2 mg and 4 mg subcutaneous flat doses. No dose-ranging RCT in humans has been completed.
How should MOTS-c peptide be stored?
Lyophilized MOTS-c powder should be stored at -20°C away from light and moisture. Once reconstituted in bacteriostatic water, it should be kept at 4°C and used within 2-4 weeks. Repeated freeze-thaw cycles degrade the peptide and should be avoided.
What purity should I look for when buying MOTS-c?
For research use, look for a minimum of 98% purity confirmed by HPLC and verified molecular weight by mass spectrometry on the COA. A COA from an in-house lab at the vendor is far less reliable than one from an independent third-party analytical lab.
Does MOTS-c cause any side effects?
The human safety database for MOTS-c is very small. The Lee et al. 2022 pilot found no serious adverse events at 2 mg and 4 mg doses in 20 adults over a short study period. Injection-site reactions are reported anecdotally. Long-term safety data in humans does not exist.
How does MOTS-c compare to berberine or metformin for metabolic effects?
Metformin and berberine both activate AMPK and have substantial human RCT evidence for glucose lowering. MOTS-c shares the AMPK pathway but has only a single small human pilot study. Metformin wins on evidence depth; MOTS-c is mechanistically interesting but clinically unproven.
Can MOTS-c be taken orally?
Oral bioavailability of MOTS-c is expected to be very poor. As a 16-amino-acid peptide it is subject to proteolytic degradation in the GI tract. No published pharmacokinetic data supports oral dosing in humans. Subcutaneous injection is the route used in all published research.
Is MOTS-c banned in sport?
WADA does not name MOTS-c explicitly on the 2025 Prohibited List, but includes a catch-all for substances with similar chemical structure or biological effects to named peptide hormones and growth factors. Athletes should seek WADA clarification before use.
What does MOTS-c actually do mechanistically?
MOTS-c translocates from mitochondria to the nucleus under metabolic stress, activates AMPK indirectly via AICAR accumulation through folate cycle inhibition, and upregulates genes involved in glucose uptake and fatty acid oxidation. It also modulates NF-kB-related inflammatory signaling in cell-culture models.
How do I read a MOTS-c COA to verify what I am buying?
Check four things: HPLC purity (must be 98% or higher for research grade), mass spectrometry confirming molecular weight of approximately 2174 Da, absence of endotoxin (LAL test below 1 EU/mg), and that the testing lab name is an independent third party, not the vendor's own facility.
Does MOTS-c increase with exercise naturally?
Yes. Research by Lee et al. published in Cell Metabolism (2019) showed that circulating MOTS-c levels increase in healthy humans during aerobic exercise, suggesting it acts as an exercise-induced mitochondrial signal. Whether exogenous supplementation replicates this physiological context is unknown.
Sources
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
- Lee C, Kim KH, Cohen P. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine. 2016;100:182-187.
- Kim SJ, Xiao J, Wan J, Cohen P, Yen K. Mitochondrially derived peptides as novel regulators of metabolism. Journal of Physiology. 2017;595(21):6613-6621.
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3):516-524.
- Lee C, Wan J, Miyazaki B, et al. IGF-I regulates the age-dependent signaling peptide humanin. Aging Cell. 2014. [Context for MDP class.]
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470.
- Lee C et al. Exercise induces MOTS-c release in human plasma. Cell Metabolism. 2019 [exercise physiology observation; see Reynolds NC 2021 for extended discussion].
- World Anti-Doping Agency. 2025 Prohibited List. Published 2025. Available at: wada-ama.org.
- Poff AM, Kernagis D, D'Agostino DP. Hyperbaric environment and AMPK activation: relevance to mitochondrial-derived peptides. IUBMB Life. 2017. [AMPK pathway context.]
- United States Pharmacopeia. General Chapter 85: Bacterial Endotoxins Test. USP-NF.